Print this page
-
Evolution and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential in Breast Tumor Microenvironment.
Protocol: 001839Principal Investigator:
-
Shridar Ganesan
Applicable Disease Sites: Breast -
A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer.
Protocol: 042012Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
INFORM Extended
Protocol: 042101Principal Investigator:
-
Deborah L Toppmeyer
Applicable Disease Sites: Breast -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib.
Protocol: 042106Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy.
Protocol: 042201Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
Video Education with Result Dependent dIsclosure (VERDI)
Protocol: 042207Principal Investigator:
-
Deborah L Toppmeyer
Applicable Disease Sites: Breast
Colon
Kidney
Melanoma, Skin
Ovary
Pancreas
Prostate
Soft Tissue -
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence.
Protocol: 042209Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
Pilot Study to Investigate the Metabolic Pathways in Hormone Receptor-Positive/HER2-Negative Breast Cancer.
Protocol: 042210Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.
Protocol: 042211Principal Investigator:
-
Coral Omene
Applicable Disease Sites: Breast -
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE).
Protocol: 042305Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
An Adjuvant Endocrine-Based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer.
Protocol: 042312Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast -
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-Human Epidermal Growth Factor Receptor 2 (anti-HER2) Antibody-Drug Conjugate (ADC), in Previously Treated Subjects with HER2-Positive or HER2-Low Unresectable or Metastatic Breast Cancer.
Protocol: 042314Principal Investigator:
-
Mridula A George
Applicable Disease Sites: Breast
- 1
- 2